Ultrahuman, a health technology startup, has raised $17.5 million in funding from Alpha Wave Incubation (AWI), Steadview Capital, and existing investors Nexus Venture Partners, Blume Ventures, and Utsav Somani's iSeed fund.

The Bengaluru-based company, which uses a wearable device to help users measure their metabolic fitness, will use the funds to expand geographically and improve its biomarker technology.

Tiger Global's Scott Schleifer, Cred's Kunal Shah, Udaan's Sujeet Kumar, Zomato's Deepinder Goyal, and Unacademy's Gaurav Munjal were among the angel investors who participated in the round.

The company has raised a total of $25 million, including the most recent round.
Ultrahuman's wearable device, founded by Mohit Kumar and Vatsal Singhal, helps people optimise their exercise and nutrition based on glucose biomarkers. Kumar and Singhjal were also co-founders of Runnr, a provider of hyper-local logistics services that merged with food delivery app Zomato in 2017.

Ultrahuman, which was launched in India in June, has already amassed thousands of users on its waitlist, according to the company.

“The metabolic health crisis is one of the largest healthcare crises that exists today. Over a billion people in the world suffer from a metabolic health disorder. Metabolic disorders contribute to almost 85% of all chronic diseases in the world,” the company said in a statement.

“By helping people understand how food and exercise affects their metabolic health, people would be able to make informed choices about what they eat and their activity levels," it added.

According to the company, this approach is a geography/diet-agnostic way to help people eat and exercise better.

“Biomarkers will change how the fitness and the healthcare industry works. By being able to continuously monitor their biomarkers like glucose, users can not only avoid chronic diseases but make lifestyle changes that help them improve their fitness levels for longevity and performance,” Kumar, the cofounder and CEO of Ultrahuman, said.

“We are thrilled to back what could be a pioneering biomarker-driven global healthcare business. Their dual obsessiveness around product engineering and customer experience is already showing results in terms of product market fit and retention,” said Navroz D. Udwadia, cofounder, Falcon Edge Capital. AWI is backed by DisruptAD and managed by Falcon Edge.

“Ultrahuman’s biosensor-enabled, data-first model, in our view, is the future of any personalized healthcare ecosystem,” said Ravi Mehta, founder and MD, Steadview Capital.